Finding Value in the Most Overlooked Elements of the Due Diligence Process

Intellectual property rights, especially patents, frequently form the foundation of value in a life sciences company. If conducted with eventual commercial success in mind, a due diligence review of an IP portfolio can enable an investor to assess more accurately the present and future value of the technology and IP associated with an investment. Often times however, little thought is given as to how to leverage the harvested intelligence in the commercialization process of the acquired technology after the deal. This panel discussed:

• The IP due diligence process – what to expect and preparing for the unexpected
  
• Working the IP – identifying and valuing know-how to execute the IP
  
• The technology factor – working with R & D during and after the diligence process

Presenters included:

• Jana Diesner, Carnegie Mellon University
  
• James Ewing, Senior Counsel, Biotechnology & Pharmaceutical Practice, Foley
  
• John Gutkoski, Partner, IP Litigation Practice, Foley
  
• Antoinette Konski, Partner, Biotechnology & Pharmaceutical Practice, Foley
  
• Dr. Roxanne Spencer, Ph.D., Patent Manager, Antisoma, Inc.
  
• Christopher Verni, Patent Counsel, Genzyme Corporation